Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(6):456-459
DOI: 10.5428/pcar20180616
A preliminary study on the mode of pharmaceutical care based on the two-system drug interaction software
1. CHEN DongLian1(1.Department of Pharmacy,Affiliated Hospital of Youjiang National Medical University,Guangxi Baise 533000,China ping.pig8610@aliyun.com)
2. 2(2.Department of Pharmacy, Renji Hospital Affiliated to School of Medicine,Shanghai Jiaotong University,Shanghai 200127,China ping.pig8610@aliyun.com)
3. GU ZhiChun2(2.Department of Pharmacy, Renji Hospital Affiliated to School of Medicine,Shanghai Jiaotong University,Shanghai 200127,China guzhichun213@163.com)
4. GAN Yi3( 3.Department of Pharmacy, People’s Hospital of Qionghai City,Hainan Province,Hainan,Qionghai 571400,China )
5. XU ShanShan4( 4.Department of Pharmacy, Shanghai Deji Hospital Affiliated to Ninth Clinical Medical College of Qingdao University,Shanghai 200331,China )
6. ZHENG XiaoYuan5( 5.Department of Pharmacy,Affiliated Hospital of Jiangnan University,Jiangsu,Wuxi 214000,China )
7. LIU XiaoYan2( 2.Department of Pharmacy, Renji Hospital Affiliated to School of Medicine,Shanghai Jiaotong University,Shanghai 200127,China )
ABSTRACT  Objective: To explore a better mode of pharmaceutical care based on previous researches,so as to improve the safety of clinical medication.Methods: Potential drug interactions were screened by Micromedex and Lexicomp databases for those patients stayed in the cardiovascular intensive care unit (CICU).For those drug interactions at contraindicated,major and moderate or X,D and C screened levels,optimization suggestions or monitoring measures were recommended in accordance with patient conditions.Results: With this novel mode of pharmaceutical care,clinical pharmacists could offer pharmaceutical care rapidly,accurately and effectively.Conclusion: The mode of pharmaceutical care based on the two-system drug interaction software could enable clinical pharmacists to provide more rapid,accurate and effective intervention in clinical practice.
Welcome to PCAR! You are the number 180 reader of this article!
Please cite this article as:
CHEN DongLian1,2,GU ZhiChun2,GAN Yi3,XU ShanShan4,ZHENG XiaoYuan5,LIU XiaoYan2,. A preliminary study on the mode of pharmaceutical care based on the two-system drug interaction software[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(6): 456-459.
References:
1. GU ZhiChun,CUI Min,LIU XiaoYan,et al.Pharmaceutical care based on drug interaction filter application[J].Pharm Care Res,2015,15(3):182-184.In Chinese with English abstract.
2. Patel R I,Beckett R D.Evaluation of resources for analyzing drug interactions[J].J Med Libr Assoc,2016,104(4):290-295.
3. Baillargeon J,Holmes H M,LIN YuLi,et al.Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults[J]. Am J Med,2012,125(2):183-189.
4. Unge P,Svedberg L E,Nordgren A,et al.A study of the interaction of omeprazole and warfarin in anticoagulated patients[J]. Br J Clin Pharmacol,1992,34(6):509-512.
5. O’Reilly R A.Spironolactone and warfarin interaction[J].Clin Pharmacol Ther,1980,27(2):198-201.
6. Buresly K,Eisenberg M J,ZHANG Xun,et al.Bleeding complications associated with combinations of aspirin,thienopyridine derivatives,and warfarin in elderly patients following acute myocardial infarction[J].Arch Intern Med,2005,165:784-789.
7. Barry M.Rosuvastatin-warfarin drug interaction[J].Lancet,2004,363(9405):328.
8. Simon T,Verstuyft C,Mary-Krause M,et al.Genetic determinants of response to clopidogrel and cardiovascular events[J]. N Engl J Med,2009,360(4):363-375.
9. Collet J P,Hulot J S,Pena A,et al.Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study[J].Lancet,2009,373:309-317.
10. Mega J L,Close S L,Wiviott S D,et al.Cytochrome P-450 polymorphisms and response to clopidogrel[J].N Engl J Med,2009,360(4):354-362.
11. Frere C,Cuisset T,Morange P E,et al.Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome[J].Am J Cardiol,2008,101(8):1088-1093.
12. LI XueQing,Andersson T B,Ahlstrm M,et al.Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole,esomeprazole,lansoprazole,pantoprazole,and rabeprazole on human cytochrome P450 activities[J].Drug Metab Dispos,2004,32(8):821-827.
13. Kreutz R P,Stanek E J,Aubert R,et al.Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes study[J].Pharmacotherapy,2010,30(8):787-796.
14. Frelinger A L 3rd,Lee R D,Mulford D J,et al.A randomized,2-period,crossover design study to assess the effects of dexlansoprazole,lansoprazole,esomeprazole,and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers[J].J Am Coll Cardiol,2012,59(14):1304-1311.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口